Richard Helton
Family Medicine · Coalgate, OKNPI 1972545820
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,250 of the $30,860 with a category attached, or 94.8%. GSK accounts for 96.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $29,909 and has fallen 99.9% since, to $16 in 2024. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $428.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$30K
- AbbVie$347
- Novo Nordisk$214
- Actelion Pharmaceuticals US, Inc.$157
- Portola Pharmaceuticals, LLC$59
- Medtronic$50
- plus $214 from 9 others
What the payments were for
- Speaking & faculty fees$29,25095%
- Food & beverage$1,6105%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $29,820 |
| AbbVie | 17 | $347 |
| Novo Nordisk | 13 | $214 |
| Actelion Pharmaceuticals US, Inc. | 6 | $157 |
| Portola Pharmaceuticals, LLC | 2 | $59 |
| Medtronic | 1 | $50 |
| Pfizer | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $16 |
| Alkermes, Inc. | 1 | $13 |
| Exact Sciences | 1 | $13 |
| Mannkind Corporation | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$16,687
How this compares
$30,860 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 134 | $142,199 |
| OzempicSemaglutide | 118 | $141,874 |
| EliquisApixaban | 289 | $136,126 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $74,275 |
| JanuviaSitagliptin Phosphate | 100 | $72,901 |
| LinzessLinaclotide | 89 | $54,469 |
| JardianceEmpagliflozin | 101 | $52,529 |
| TrulicityDulaglutide | 34 | $40,849 |
| RexultiBrexpiprazole | 25 | $34,114 |
| FarxigaDapagliflozin Propanediol | 45 | $29,567 |
| TrintellixVortioxetine Hydrobromide | 107 | $26,082 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $23,719 |
| GemtesaVibegron | 68 | $19,776 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 819 | $18,558 |
| Potassium Chloride | 591 | $14,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $214 | $141,874118 claims |
| PfizerEliquis | $49 | $136,126289 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29,820 | $81,201116 claims |
| AbbVieLinzess | $347 | $54,46989 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $28 | $34,11425 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $19,77668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Coalgate
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.